B7-H6/CD3 T-cell Engager
A first-in-class IgG-like T-cell engager targeting B7-H6
BI 765049: B7-H6/CD3 T-cell engager
Our B7-H6/CD3 T-cell engager* acts as a bridge that selectively directs the activity of T cells toward tumor cells that express B7-H6.1
Clinical trials (monotherapy and combination therapy): our B7-H6/CD3 T-cell engager is currently being investigated in a Phase I trials as monotherapy and in combination with ezabenlimab (BI 754091)*, a programmed cell death protein-1 (PD-1) inhibitor, in patients with advanced solid tumors that express B7-H6.2,3
*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
Clinical development
Our B7-H6/CD3 T-cell engager is currently undergoing clinical investigation in a Phase I study as a monotherapy and in combination with ezabenlimab in patients with advanced solid tumors that express B7-H6.2
B7-H6/CD3 T-cell engager clinical trials
Trial number | Phase | Treatment | Patient population | Status |
|---|---|---|---|---|
I | BI 765049 ± ezabenlimab (PD-1 inhibitor) | Advanced, unresectable, and/or metastatic solid tumors (i.e. CRC, NSCLC, HCC, HNSCC, gastric carcinoma and pancreatic carcinoma) with confirmed B7-H6 expression | Recruiting | |
NCT06091930 (1454-0004)3 | I | BI 765049 ± ezabenlimab (PD-1 inhibitor) | Malignant solid tumors expressing B7-H6 | Recruiting |
CD3, cluster of differentiation 3; CRC, colorectal cancer.
You may also be interested in...
OUR PIPELINE
DLL3/CD3 T-CELL ENGAGER
ezabenlimab
Hipp S, et al. Presented at: American Association for Cancer Research Annual Meeting 2021; 2021; April 10–15. Philadelphia.
ClinicalTrials.gov. NCT04752215. https://clinicaltrials.gov/study/NCT04752215 (Accessed: February 2024)
ClinicalTrials.gov. NCT06091930. https://clinicaltrials.gov/study/NCT06091930 (Accessed: February 2024)